-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
-
Summary
-
Halozyme Therapeutics, Inc. quarterly/annual Depreciation, Depletion and Amortization history and growth rate from 2010 to 2024.
- Halozyme Therapeutics, Inc. Depreciation, Depletion and Amortization for the quarter ending December 31, 2024 was $2.62M, a 11.5% decline year-over-year.
- Halozyme Therapeutics, Inc. Depreciation, Depletion and Amortization for the twelve months ending December 31, 2024 was $10.3M, a 7.4% decline year-over-year.
- Halozyme Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2024 was $10.3M, a 7.4% decline from 2023.
- Halozyme Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2023 was $11.1M, a 70.7% increase from 2022.
- Halozyme Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2022 was $6.49M, a 117% increase from 2021.
Depreciation, Depletion and Amortization, Trailing 12 Months (USD)
Depreciation, Depletion and Amortization, Annual (USD)
Depreciation, Depletion and Amortization, YoY Annual Growth (%)